Leukocyte-Expressed β2-Adrenergic Receptors Are Essential for Survival after Acute Myocardial Injury

Circulation

Volumn 134, Issue 2, 2016, Pages 153-167

  Grisanti, Laurel A ^a   Gumpert, Anna M ^a   Traynham, Christopher J ^a   Gorsky, Joshua E ^a   Repas, Ashley A ^a   Gao, Erhe ^a   Carter, Rhonda L ^a   Yu, Daohai ^a   Calvert, John W ^b   Garciá, Andrés Pun ^c   Ibáñez, Borja ^c   Rabinowitz, Joseph E ^a   Koch, Walter J ^a   Tilley, Douglas G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

immune system; inflammation; leukocytes; myocardial infarction

Indexed keywords

ADRENERGIC RECEPTOR; BETA ARRESTIN; VASCULAR CELL ADHESION MOLECULE 1; BETA 2 ADRENERGIC RECEPTOR; HYBRID PROTEIN; METOPROLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL POPULATION; FEMALE; HEART MUSCLE INJURY; HEART RUPTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IRRADIATION; MACROPHAGE CULTURE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; SURVIVAL RATE; AGED; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; GENE VECTOR; GENETICS; HEART INFARCTION; LEUKOCYTE; MACROPHAGE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; RADIATION CHIMERA; SPLEEN; SPLENECTOMY; THERAPEUTIC USE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HEART RUPTURE; HUMANS; LEUKOCYTES; MACROPHAGES; MALE; METOPROLOL; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; NEUTROPHIL INFILTRATION; RADIATION CHIMERA; RECEPTORS, ADRENERGIC, BETA-2; RECOMBINANT FUSION PROTEINS; SPLEEN; SPLENECTOMY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84978175123     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022304     Document Type: Article

References (50)

1. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255-265. doi: 10.1038/nrcardio.2014.28.
2. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047. doi: 10.1084/jem.20070885.
3. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, Fukuda K, Sano M. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol. 2013;62:24-35. doi: 10.1016/j.yjmcc.2013.04.023.
4. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699-710.
5. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-kappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation. 2001;103:2296-2302.
6. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325:612-616. doi: 10.1126/science.1175202.
7. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-961. doi: 10.1038/nm1613.
8. Möllmann H, Nef HM, Kostin S, von Kalle C, Pilz I, Weber M, Schaper J, Hamm CW, Elsässer A. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res. 2006;71:661-671. doi: 10.1016/j.cardiores.2006.06.013.
9. Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63:1593-1603. doi: 10.1016/j.jacc.2014.01.014.
10. Padro CJ, Sanders VM. Neuroendocrine regulation of inflammation. Semin Immunol. 2014;26:357-368. doi: 10.1016/j. smim.2014.01.003.
11. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595-638.
12. Grisanti LA, Talarico JA, Carter RL, Yu JE, Repas AA, Radcliffe SW, Tang HA, Makarewich CA, Houser SR, Tilley DG.-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. J Mol Cell Cardiol. 2014;72:39-51. doi: 10.1016/j. yjmcc.2014.02.009.
13. Speidl WS, Toller WG, Kaun C, Weiss TW, Pfaffenberger S, Kastl SP, Furnkranz A, Maurer G, Huber K, Metzler H, Wojta J. Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. FASEB J. 2004;18:603-605. doi: 10.1096/fj.03-0454fje.
14. Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun. 2007;21:736-745. doi: 10.1016/j.bbi.2007.03.008.
15. Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through 2-adrenergic receptors. J Exp Med. 2014;211:2583-2598. doi: 10.1084/jem.20141132.
16. Lubahn CL, Lorton D, Schaller JA, Sweeney SJ, Bellinger DL. Targeting-and-adrenergic receptors differentially shifts Th1, Th2, and Inflammatory cytokine profiles in immune organs to attenuate adjuvant arthritis. Front Immunol. 2014;5:346. doi: 10.3389/fimmu.2014.00346.
17. Mendez-Ferrer S, Battista M, Frenette PS. Cooperation of beta(2)-and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci. 2010;1192:139-144.
18. Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008;452:442-447. doi: 10.1038/nature06685.
19. Heidt T, Sager HB, Courties G, Dutta P, Iwamoto Y, Zaltsman A, von Zur Muhlen C, Bode C, Fricchione GL, Denninger J, Lin CP, Vinegoni C, Libby P, Swirski FK, Weissleder R, Nahrendorf M. Chronic variable stress activates hematopoietic stem cells. Nat Med. 2014;20:754-758. doi: 10.1038/nm.3589.
20. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK, Ma XL, Koch WJ. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res. 2010;107:1445-1453. doi: 10.1161/CIRCRESAHA.110.223925.
21. Liggett SB, Bouvier M, Hausdorff WP, O'Dowd B, Caron MG, Lefkowitz RJ. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites. Mol Pharmacol. 1989;36:641-646.
22. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, Lefkowitz RJ. beta-arrestindependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2006;281:1261-1273. doi: 10.1074/jbc.M506576200.
23. Dutta P, Hoyer FF, Grigoryeva LS, Sager HB, Leuschner F, Courties G, Borodovsky A, Novobrantseva T, Ruda VM, Fitzgerald K, Iwamoto Y, Wojtkiewicz G, Sun Y, Da Silva N, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M. Macrophages retain hematopoietic stem cells in the spleen via VCAM-1. J Exp Med. 2015;212:497-512. doi: 10.1084/jem.20141642.
24. van der Laan AM, Ter Horst EN, Delewi R, Begieneman MP, Krijnen PA, Hirsch A, Lavaei M, Nahrendorf M, Horrevoets AJ, Niessen HW, Piek JJ. Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur Heart J. 2014;35:376-385. doi: 10.1093/eurheartj/eht331.
25. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720.
26. Ernström U, Sandberg G. Effects of adrenergic alpha-and betareceptor stimulation on the release of lymphocytes and granulocytes from the spleen. Scand J Haematol. 1973;11:275-286.
27. Modin A, Pernow J, Lundberg JM. Comparison of the acute influence of neuropeptide Y and sympathetic stimulation on the composition of blood cells in the splenic vein in vivo. Regul Pept. 1993;47:159-169.
28. Moerman EJ, Scapagnini U, De Schaepdryver AF. Adrenergic receptors in the isolated perfused dog spleen. Eur J Pharmacol. 1969;5:279-285.
29. Harris TJ, Waltman TJ, Carter SM, Maisel AS. Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive heart failure. J Am Coll Cardiol. 1995;26:102-109.
30. Bakovic D, Pivac N, Zubin Maslov P, Breskovic T, Damonja G, Dujic Z. Spleen volume changes during adrenergic stimulation with low doses of epinephrine. J Physiol Pharmacol. 2013;64:649-655.
31. Rogausch H, del Rey A, Oertel J, Besedovsky HO. Norepinephrine stimulates lymphoid cell mobilization from the perfused rat spleen via beta-adrenergic receptors. Am J Physiol. 1999;276(pt 2):R724-R730.
32. Zebrack JS, Munger M, Macgregor J, Lombardi WL, Stoddard GP, Gilbert EM. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. Pharmacotherapy. 2009;29:883-890. doi: 10.1592/phco.29.8.883.
33. Landmann R, Dürig M, Gudat F, Wesp M, Harder F. Beta-adrenergic regulation of the blood lymphocyte phenotype distribution in normal subjects and splenectomized patients. Adv Exp Med Biol. 1985;186:1051-1062.
34. Van Tits LJ, Michel MC, Grosse-Wilde H, Happel M, Eigler FW, Soliman A, Brodde OE. Catecholamines increase lymphocyte beta 2-adrenergic receptors via a beta 2-adrenergic, spleen-dependent process. Am J Physiol. 1990;258(pt 1):E191-E202.
35. Tsai MS, Chou SE, Lai HS, Jeng LB, Lin CL, Kao CH. Long-term risk of acute coronary syndrome in splenectomized patients due to splenic injury. Medicine. 2015;94:e610.
36. Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet. 1977;2:127-129.
37. Zhang X, Szeto C, Gao E, Tang M, Jin J, Fu Q, Makarewich C, Ai X, Li Y, Tang A, Wang J, Gao H, Wang F, Ge XJ, Kunapuli SP, Zhou L, Zeng C, Xiang KY, Chen X. Cardiotoxic and cardioprotective features of chronic-adrenergic signaling. Circ Res. 2013;112:498-509. doi: 10.1161/CIRCRESAHA.112.273896.
38. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure: reversal of sympathetic-induced alterations of immunologic function. Circulation. 1994;90:1774-1780.
39. Maisel AS, Harris T, Rearden CA, Michel MC. Beta-adrenergic receptors in lymphocyte subsets after exercise: alterations in normal individuals and patients with congestive heart failure. Circulation. 1990;82:2003-2010.
40. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182-186. doi: 10.1016/j. ijcard.2004.08.053.
41. von Haehling S, Schefold JC, Jankowska E, Doehner W, Springer J, Strohschein K, Genth-Zotz S, Volk HD, Poole-Wilson P, Anker SD. Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One. 2009;4:e6411. doi: 10.1371/journal.pone.0006411.
42. Shaw SM, Coppinger T, Waywell C, Dunne L, Archer LD, Critchley WR, Yonan N, Fildes JE, Williams SG. The effect of betablockers on the adaptive immune system in chronic heart failure. Cardiovasc Ther. 2009;27:181-186. doi: 10.1111/j.1755-5922.2009.00089.x.
43. Scali S, Patel V, Neal D, Bertges D, Ho K, Jorgensen JE, Cronenwett J, Beck A. Preoperative-blockers do not improve cardiac outcomes after major elective vascular surgery and may be harmful. J Vasc Surg. 2015;62:166-176.e2. doi: 10.1016/j.jvs.2015.01.053.
44. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;130:e431-e432.]. Circulation. 2014;130:2354-2394. doi: 10.1161/CIR.0000000000000133.
45. Zhang Q, Xiang J, Wang X, Liu H, Hu B, Feng M, Fu Q. Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats. Br J Pharmacol. 2010;160:1561-1572. doi: 10.1111/j.1476-5381.2010.00813.x.
46. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation. 2004;110:1083-1090. doi: 10.1161/01. CIR.0000139844.15045.F9.
47. Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, Xiao RP, Lakatta EG, Talan MI. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther. 2008;325:491-499. doi: 10.1124/jpet.107.135335.
48. Ahmet I, Morrell C, Lakatta EG, Talan MI. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther. 2009;331:178-185.
49. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, Matera MG. Effects of the new ultra-long-acting beta-AR agonist indacaterol in chronic treatment alone or in combination with the beta-AR blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015; 172:3627-3637.
50. Bhushan S, Kondo K, Predmore BL, Zlatopolsky M, King AL, Pearce C, Huang H, Tao YX, Condit ME, Lefer DJ. Selective beta2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2012;32:1865-1874. doi: 10.1161/ATVBAHA.112.251769.